Clinical characteristics of patients with newly diagnosed lymphomas in the prospective cohort with no known CNS disease
| Variable . | All . | CSF NGS-MRD assay . | P . | |
|---|---|---|---|---|
| Positive . | Negative . | |||
| Patients, n | 22 | 8 | 14 | |
| Age, y, median (range) | 63 (27-83) | 53 (38-76) | 67 (27-83) | .34 |
| Female, n (%) | 7 (32) | 1 (13) | 6 (43) | .19 |
| Histology, n (%) | .76 | |||
| DLBCL | 10 (45) | 3 (38) | 7 (50) | — |
| HGBCL* | 7 (32) | 4 (50) | 3 (21) | — |
| THRLBCL | 1 (5) | — | 1 (7) | — |
| Plasmablastic lymphoma | 1 (5) | — | 1 (7) | — |
| BL | 3 (14) | 1 (13) | 2 (14) | — |
| CNS-IPI, n (%)† | .99 | |||
| Low | 2 (11) | 1 (14) | 1 (8) | — |
| Intermediate | 8 (42) | 3 (43) | 5 (42) | — |
| High | 9 (47) | 3 (43) | 6 (50) | — |
| LDH, U/mL, median (range) | 401 (144-1619) | 480 (191-1619) | 287 (144-1553) | .27 |
| MRI brain performed, n (%) | 11 (50) | 4 (50) | 7 (50) | .99 |
| First-line chemotherapy, n (%) | .99 | |||
| R-CHOP | 8 (36) | 3 (38) | 5 (36) | — |
| DA-EPOCH-R | 12 (55) | 4 (50) | 8 (57) | — |
| Other‡ | 2 (9) | 1 (13) | 1 (7) | — |
| CNS prophylaxis | .99 | |||
| High-dose methotrexate | 6 (27) | 2 (25) | 4 (29) | — |
| IT only | 14 (64) | 5 (63) | 9 (64) | — |
| None (declined) | 2 (9) | 1 (13) | 1 (7) | — |
| IT injections, n, median (range) | 4 (1-9) | 3.5 (2-9) | 4 (1-6) | .47 |
| CSF cell count per cubic millimeter | ||||
| WBC, median (range) | 1 (0-3) | 1 (0-3) | 0 (0-3) | .38 |
| RBC, median (range) | 14 (0-331) | 31 (0-299) | 8 (0-331) | .38 |
| Variable . | All . | CSF NGS-MRD assay . | P . | |
|---|---|---|---|---|
| Positive . | Negative . | |||
| Patients, n | 22 | 8 | 14 | |
| Age, y, median (range) | 63 (27-83) | 53 (38-76) | 67 (27-83) | .34 |
| Female, n (%) | 7 (32) | 1 (13) | 6 (43) | .19 |
| Histology, n (%) | .76 | |||
| DLBCL | 10 (45) | 3 (38) | 7 (50) | — |
| HGBCL* | 7 (32) | 4 (50) | 3 (21) | — |
| THRLBCL | 1 (5) | — | 1 (7) | — |
| Plasmablastic lymphoma | 1 (5) | — | 1 (7) | — |
| BL | 3 (14) | 1 (13) | 2 (14) | — |
| CNS-IPI, n (%)† | .99 | |||
| Low | 2 (11) | 1 (14) | 1 (8) | — |
| Intermediate | 8 (42) | 3 (43) | 5 (42) | — |
| High | 9 (47) | 3 (43) | 6 (50) | — |
| LDH, U/mL, median (range) | 401 (144-1619) | 480 (191-1619) | 287 (144-1553) | .27 |
| MRI brain performed, n (%) | 11 (50) | 4 (50) | 7 (50) | .99 |
| First-line chemotherapy, n (%) | .99 | |||
| R-CHOP | 8 (36) | 3 (38) | 5 (36) | — |
| DA-EPOCH-R | 12 (55) | 4 (50) | 8 (57) | — |
| Other‡ | 2 (9) | 1 (13) | 1 (7) | — |
| CNS prophylaxis | .99 | |||
| High-dose methotrexate | 6 (27) | 2 (25) | 4 (29) | — |
| IT only | 14 (64) | 5 (63) | 9 (64) | — |
| None (declined) | 2 (9) | 1 (13) | 1 (7) | — |
| IT injections, n, median (range) | 4 (1-9) | 3.5 (2-9) | 4 (1-6) | .47 |
| CSF cell count per cubic millimeter | ||||
| WBC, median (range) | 1 (0-3) | 1 (0-3) | 0 (0-3) | .38 |
| RBC, median (range) | 14 (0-331) | 31 (0-299) | 8 (0-331) | .38 |
DA-EPOCH-R, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab; IT, intrathecal; LDH, lactate dehydrogenase; MRI, magnetic resonance imaging; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; THRLBCL, T-cell/histiocyte-rich large B-cell lymphoma.
With MYC and BCL2 and/or BCL6 rearrangements.
Calculated for DLBCL, HGBCL, THRLBCL, and plasmablastic lymphoma only.
One patient each for rituximab alone and R-CODOX-M/IVAC (rituximab plus cyclophosphamide, doxorubicin, vincristine, methotrexate/ifosfamide, etoposide, and high-dose cytarabine).